Low-dose belimumab for patients with systemic lupus erythematosus at low disease activity: protocol for a multicentre, randomised, double-blind, placebo-controlled clinical trial

Fangfang Sun, Wenyan Huang, Jie Chen, Liling Zhao, Danting Zhang, Xiaodong Wang, Weiguo Wan, Sheng-Ming Dai, Sheng Chen, Ting Li, Shuang Ye, Fangfang Sun, Wenyan Huang, Jie Chen, Liling Zhao, Danting Zhang, Xiaodong Wang, Weiguo Wan, Sheng-Ming Dai, Sheng Chen, Ting Li, Shuang Ye

Abstract

Introduction: SLE is a chronic inflammatory systemic autoimmune disease with relapsing-remitting pattern. B-lymphocyte stimulator was involved in the pathogenesis of SLE. The humanised monoclonal antibody belimumab with 10 mg/kg was effective for active patients. However, the efficacy of low-dose belimumab for prevention of disease flares in patients with SLE with low disease activity is to be explored.

Methods and analysis: This is a multicentre, randomised, double-blind, placebo-controlled clinical trial. Patients who have Safety of Estrogens in Lupus Erythematosus National Assessment-Systemic Lupus Erythematosus Disease Activity Index (SELENA-SLEDAI) scores no higher than 6; with no A score or no more than one B score on the British Isles Lupus Assessment Group (BILAG) scale; and who are treated with prednisone (≤20 mg per day) at screening will be enrolled. 334 adults will be randomly assigned in a 1:1 ratio to receive intravenous 120 mg belimumab or placebo (saline) arm on weeks 0, 2, and 4, and then every 4 weeks until 48 weeks, with standard of care. The primary outcome measure is a composite index of severe or mild-to-moderate disease flares (SELENA-SLEDAI Flare Index) within 52 weeks. Secondary outcomes include the percentage of severe flare, the percentage of mild-to-moderate flare, time to first disease flare, changes in prednisone dose, SELENA-SLEDAI, as well as BILAG score, the percentage of patients achieving prednisone free and safety analysis.

Ethics and dissemination: The protocol has been approved by the Ethics Committee of the Renji Hospital, Huashan Hospital and the Sixth People's Hospital. The trial has been registered and the detailed information is available at https://clinicaltrialsgov/ct2/show/NCT04515719. The results of this clinical trial will be submitted for publication in peer-reviewed journals and key findings will also be presented at national and international conferences.

Trial registration number: NCT04515719.

Keywords: biological products; lupus erythematosus; systemic; therapeutics.

Conflict of interest statement

Competing interests: None declared.

© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

References

    1. Petri M, Stohl W, Chatham W, et al. . Association of plasma B lymphocyte stimulator levels and disease activity in systemic lupus erythematosus. Arthritis Rheum 2008;58:2453–9. 10.1002/art.23678
    1. Navarra SV, Guzmán RM, Gallacher AE, et al. . Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet 2011;377:721–31. 10.1016/S0140-6736(10)61354-2
    1. Furie R, Petri M, Zamani O, et al. . A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum 2011;63:3918–30. 10.1002/art.30613
    1. Oon S, Huq M, Golder V, et al. . Lupus low disease activity state (LLDAS) discriminates responders in the BLISS-52 and BLISS-76 phase III trials of belimumab in systemic lupus erythematosus. Ann Rheum Dis 2019;78:629–33. 10.1136/annrheumdis-2018-214427
    1. Franklyn K, Lau CS, Navarra SV, et al. . Definition and initial validation of a lupus low disease activity state (LLDAS). Ann Rheum Dis 2016;75:1615–21. 10.1136/annrheumdis-2015-207726
    1. Zhang F, Bae S-C, Bass D, et al. . A pivotal phase III, randomised, placebo-controlled study of belimumab in patients with systemic lupus erythematosus located in China, Japan and South Korea. Ann Rheum Dis 2018;77:355–63. 10.1136/annrheumdis-2017-211631
    1. Arnaud L, Tektonidou MG. Long-term outcomes in systemic lupus erythematosus: trends over time and major contributors. Rheumatology 2020;59:v29–38. 10.1093/rheumatology/keaa382
    1. Walpole SC, Prieto-Merino D, Edwards P, et al. . The weight of nations: an estimation of adult human biomass. BMC Public Health 2012;12:439. 10.1186/1471-2458-12-439
    1. Petri M, Orbai A-M, Alarcón GS, et al. . Derivation and validation of the systemic lupus international collaborating clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum 2012;64:2677–86. 10.1002/art.34473
    1. Bombardier C, Gladman DD, Urowitz MB, et al. . Derivation of the SLEDAI. A disease activity index for lupus patients. Arthritis & Rheumatism 1992;35:630–40. 10.1002/art.1780350606
    1. Hay EM, Bacon PA, Gordon C, et al. . The BILAG index: a reliable and valid instrument for measuring clinical disease activity in systemic lupus erythematosus. Q J Med 1993;86:447–58.
    1. Sun F, Wang HJ, Liu Z, et al. . Safety and efficacy of metformin in systemic lupus erythematosus: a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Rheumatol 2020;2:e210–6. 10.1016/S2665-9913(20)30004-7
    1. van Vollenhoven RF, Hahn BH, Tsokos GC, et al. . Efficacy and safety of ustekinumab, an IL-12 and IL-23 inhibitor, in patients with active systemic lupus erythematosus: results of a multicentre, double-blind, phase 2, randomised, controlled study. Lancet 2018;392:1330–9. 10.1016/S0140-6736(18)32167-6
    1. Wallace DJ, Furie RA, Tanaka Y, et al. . Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet 2018;392:222–31. 10.1016/S0140-6736(18)31363-1
    1. Khamashta M, Merrill JT, Werth VP, et al. . Sifalimumab, an anti-interferon-α monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomised, double-blind, placebo-controlled study. Ann Rheum Dis 2016;75:1909–16. 10.1136/annrheumdis-2015-208562
    1. Furie R, Khamashta M, Merrill JT, et al. . Anifrolumab, an Anti-Interferon-α receptor monoclonal antibody, in moderate-to-severe systemic lupus erythematosus. Arthritis Rheumatol 2017;69:376–86. 10.1002/art.39962
    1. Wallace DJ, Kalunian K, Petri MA, et al. . Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study. Ann Rheum Dis 2014;73:183–90. 10.1136/annrheumdis-2012-202760
    1. Sun F, Chen Y, Wu W, et al. . Varicella zoster virus infections increase the risk of disease flares in patients with SLE: a matched cohort study. Lupus Sci Med 2019;6:e000339. 10.1136/lupus-2019-000339
    1. Wang H, Li T, Chen S, et al. . Neutrophil extracellular trap mitochondrial DNA and its autoantibody in systemic lupus erythematosus and a proof-of-concept trial of metformin. Arthritis Rheumatol 2015;67:3190–200. 10.1002/art.39296
    1. Sun F, Zhang D, Wang H, et al. . Attaining treat-to-target endpoints with metformin in lupus patients: a pooled analysis. Clin Exp Rheumatol 2021. [Epub ahead of print: 07 12 2021].
    1. Fanouriakis A, Adamichou C, Koutsoviti S, et al. . Low disease activity-irrespective of serologic status at baseline-associated with reduction of corticosteroid dose and number of flares in patients with systemic lupus erythematosus treated with belimumab: a real-life observational study. Semin Arthritis Rheum 2018;48:467–74. 10.1016/j.semarthrit.2018.02.014
    1. Tani C, Elefante E, Signorini V, et al. . Glucocorticoid withdrawal in systemic lupus erythematosus: are remission and low disease activity reliable starting points for stopping treatment? A real-life experience. RMD Open 2019;5:e000916. 10.1136/rmdopen-2019-000916
    1. Ponticelli C, Moroni G, Banfi G. Discontinuation of therapy in diffuse proliferative lupus nephritis. Am J Med 1988;85:275. 10.1016/S0002-9343(88)80366-8
    1. Steiman AJ, Urowitz MB, Ibañez D, et al. . Prolonged clinical remission in patients with systemic lupus erythematosus. J Rheumatol 2014;41:1808–16. 10.3899/jrheum.131137
    1. Mathian A, Pha M, Haroche J, et al. . Withdrawal of low-dose prednisone in SLE patients with a clinically quiescent disease for more than 1 year: a randomised clinical trial. Ann Rheum Dis 2020;79:339–46. 10.1136/annrheumdis-2019-216303
    1. Tselios K, Gladman DD, Su J, et al. . Gradual glucocorticosteroid withdrawal is safe in clinically quiescent systemic lupus erythematosus. ACR Open Rheumatol 2021;3:550–7. 10.1002/acr2.11267
    1. Dixon WG, Abrahamowicz M, Beauchamp M-E, et al. . Immediate and delayed impact of oral glucocorticoid therapy on risk of serious infection in older patients with rheumatoid arthritis: a nested case-control analysis. Ann Rheum Dis 2012;71:1128–33. 10.1136/annrheumdis-2011-200702

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe